Evidence map›Paper›PMID 39705164›Full record

ReviewAnnual review of immunology2025

SARS-CoV-2: The Interplay Between Evolution and Host Immunity.

James Brett Case, Shilpi Jain, Mehul S Suthar, Michael S Diamond

Abstract readReview
In one paragraph

Review in Annual review of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. COVID-19, the disease that changed the world.Medicine and pharmacy reports · 2026
    Review
  10. Article
  11. Observational
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; email: diamond@wusm.wustl.edu.
Shilpi JainEmory Vaccine Center, Emory National Primate Research Center, Atlanta, Georgia, USA.
Mehul S SutharEmory Vaccine Center, Emory National Primate Research Center, Atlanta, Georgia, USA.
Michael S DiamondDepartment of Pathology & Immunology; Department of Molecular Microbiology; and Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3M
The Development and Evaluation of Pan-Coronavirus VaccinesP01AI168347 · NIAID · WASHINGTON UNIVERSITY · PI Michael S Diamond, Sean PJ Whelan · 2022 to 2026
$15.9M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
NIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93021C00017NIAID NIH HHS P01 AI168347NIAID NIH HHS R01 AI157155NIH HHS 75N93021C00014NIH HHS 75N93021C00017NIH HHS P51 OD011132
6 · The paper itself

Abstract

The persistence of SARS-CoV-2 infections at a global level reflects the repeated emergence of variant strains encoding unique constellations of mutations. These variants have been generated principally because of a dynamic host immune landscape, the countermeasures deployed to combat disease, and selection for enhanced infection of the upper airway and respiratory transmission. The resulting viral diversity creates a challenge for vaccination efforts to maintain efficacy, especially regarding humoral aspects of protection. Here, we review our understanding of how SARS-CoV-2 has evolved during the pandemic, the immune mechanisms that confer protection, and the impact viral evolution has had on transmissibility and adaptive immunity elicited by natural infection and/or vaccination. Evidence suggests that SARS-CoV-2 evolution initially selected variants with increased transmissibility but currently is driven by immune escape. The virus likely will continue to drift to maintain fitness until countermeasures capable of disrupting transmission cycles become widely available.

Indexed as

COVID-19SARS-CoV-2Adaptive ImmunityAnimalsCOVID-19 VaccinesEvolution, MolecularHost-Pathogen InteractionsHumansImmune EvasionMutationPandemicsCOVID-19 VaccinesevolutionimmunityprotectionSARS-CoV-2vaccinesvariants

Identifiers

PMID39705164
PMCPMC13456083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.